Comprehensive behavioral characterization of an APP/PS-1 double knock-in mouse model of Alzheimer's disease

Alzheimer's Research and Therapy

Volumn 5, Issue 3, 2013, Pages

  Webster, Scott J ^a   Bachstetter, Adam D ^a   Van Eldik, Linda J ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer's disease; amyloid precursor protein presenilin 1; anxiety behavior; cognition; learning and memory; motor behavior; recognition memory; spatial reference memory; transgenic mouse model

Indexed keywords

AMYLOID PRECURSOR PROTEIN; PRESENILIN 1;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; APTITUDE TEST; ARTICLE; COGNITION; DISEASE COURSE; GENOTYPE; GRIP STRENGTH; MAZE TEST; MEMORY; MOBILIZATION; MOTOR PERFORMANCE; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; SPATIAL MEMORY;

EID: 84879990946     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt182     Document Type: Article

References (156)

1. Transgenic mouse models of Alzheimer's disease. Elder GA, Gama Sosa MA, De Gasperi R, Mt Sinai J Med 2010 77 69 81 10.1002/msj.20159 20101721
2. Age-dependent impairment of spine morphology and synaptic plasticity in hippocampal CA1 neurons of a presenilin 1 transgenic mouse model of Alzheimer's disease. Auffret A, Gautheron V, Repici M, Kraftsik R, Mount HT, Mariani J, Rovira C, J Neurosci 2009 29 10144 10152 10.1523/JNEUROSCI.1856-09.2009 19675248
3. Combination therapy prevents amyloid-dependent and -independent structural changes. Malthankar-Phatak G, Poplawski S, Toraskar N, Siman R, Neurobiol Aging 2012 33 1273 1283 10.1016/j.neurobiolaging.2010.12.007 21257234
4. Synaptotrophic effects of human amyloid beta protein precursors in the cortex of transgenic mice. Mucke L, Masliah E, Johnson WB, Ruppe MD, Alford M, Rockenstein EM, Forss-Petter S, Pietropaolo M, Mallory M, Abraham CR, Brain Res 1994 666 151 167 10.1016/0006-8993(94)90767-6 7882025
5. Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nalbantoglu J, Tirado-Santiago G, Lahsaini A, Poirier J, Goncalves O, Verge G, Momoli F, Welner SA, Massicotte G, Julien JP, Shapiro ML, Nature 1997 387 500 505 10.1038/387500a0 9168112
6. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, Kim G, Ratovitsky T, Davenport F, Nordstedt C, Seeger M, Hardy J, Levey AI, Gandy SE, Jenkins NA, Copeland NG, Price DL, Sisodia SS, Neuron 1996 17 181 190 10.1016/S0896-6273(00)80291-3 8755489
7. Overexpression of wild type but not an FAD mutant presenilin-1 promotes neurogenesis in the hippocampus of adult mice. Wen PH, Shao X, Shao Z, Hof PR, Wisniewski T, Kelley K, Friedrich VL, Ho L Jr, Pasinetti GM, Shioi J, Robakis NK, Elder GA, Neurobiol Dis 2002 10 8 19 10.1006/nbdi.2002.0490 12079399
8. Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a 'humanized' Aβ sequence. Reaume AG, Howland DS, Trusko SP, Savage MJ, Lang DM, Greenberg BD, Siman R, Scott RW, J Biol Chem 1996 271 23380 23388 10.1074/jbc.271.38.23380 8798542
9. Presenilin-1 P264L knock-in mutation: differential effects on aβ production, amyloid deposition, and neuronal vulnerability. Siman R, Reaume AG, Savage MJ, Trusko S, Lin YG, Scott RW, Flood DG, J Neurosci 2000 20 8717 8726 11102478
10. Endoplasmic reticulum stress-induced cysteine protease activation in cortical neurons: effect of an Alzheimer's disease-linked presenilin-1 knock-in mutation. Siman R, Flood DG, Thinakaran G, Neumar RW, J Biol Chem 2001 276 44736 44743 10.1074/jbc.M104092200 11574534
11. FAD mutant PS-1 gene-targeted mice: increased Aβ42 and Aβ deposition without APP overproduction. Flood DG, Reaume AG, Dorfman KS, Lin YG, Lang DM, Trusko SP, Savage MJ, Annaert WG, De Strooper B, Siman R, Scott RW, Neurobiol Aging 2002 23 335 348 10.1016/S0197-4580(01)00330-X 11959395
12. Aβ solubility and deposition during AD progression and in APPxPS-1 knock-in mice. Murphy MP, Beckett TL, Ding Q, Patel E, Markesbery WR, St Clair DK, LeVine H, Keller JN, Neurobiol Dis 2007 27 301 311 10.1016/j.nbd.2007.06.002 17651976
13. Gamma-secretase subunit composition and distribution in the presenilin wild-type and mutant mouse brain. Siman R, Salidas S, Neuroscience 2004 129 615 628 10.1016/j.neuroscience.2004.08.028 15541883
14. Long-lasting impairment in hippocampal neurogenesis associated with amyloid deposition in a knock-in mouse model of familial Alzheimer's disease. Zhang C, McNeil E, Dressler L, Siman R, Exp Neurol 2007 204 77 87 10.1016/j.expneurol.2006.09.018 17070803
15. Effects of short-term western diet on cerebral oxidative stress and diabetes related factors in APP × PS1 knock-in mice. Studzinski CM, Li F, Bruce-Keller AJ, Fernandez-Kim SO, Zhang L, Weidner AM, Markesbery WR, Murphy MP, Keller JN, J Neurochem 2009 108 860 866 10.1111/j.1471-4159.2008.05798.x 19046405
16. Reduction in neuronal L-type calcium channel activity in a double knock-in mouse model of Alzheimer's disease. Thibault O, Pancani T, Landfield PW, Norris CM, Biochim Biophys Acta 2012 1822 546 549 10.1016/j.bbadis.2012.01. 004 22265986
17. Early stage drug treatment that normalizes proinflammatory cytokine production attenuates synaptic dysfunction in a mouse model that exhibits age-dependent progression of Alzheimer's disease-related pathology. Bachstetter AD, Norris CM, Sompol P, Wilcock DM, Goulding D, Neltner JH, St Clair D, Watterson DM, Van Eldik LJ, J Neurosci 2012 32 10201 10210 10.1523/JNEUROSCI. 1496-12.2012 22836255
18. Cognitive impairment in humanized APP × PS1 mice is linked to Aβ(1-42) and NOX activation. Bruce-Keller AJ, Gupta S, Knight AG, Beckett TL, McMullen JM, Davis PR, Murphy MP, Van Eldik LJ, St Clair D, Keller JN, Neurobiol Dis 2011 44 317 326 10.1016/j.nbd.2011.07.012 21798347
19. Novel object recognition as a facile behavior test for evaluating drug effects in AβPP/PS1 Alzheimer's disease mouse model. Zhang R, Xue G, Wang S, Zhang L, Shi C, Xie X, J Alzheimers Dis 2012 31 801 812 22710911
20. When is the hippocampus involved in recognition memory? Barker GR, Warburton EC, J Neurosci 2011 31 10721 10731 10.1523/JNEUROSCI.6413-10.2011 21775615
21. Exposing rats to a predator impairs spatial working memory in the radial arm water maze. Diamond DM, Park CR, Heman KL, Rose GM, Hippocampus 1999 9 542 552 10.1002/(SICI)1098-1063(1999)9:5<542::AID-HIPO8>3.0.CO;2-N 10560925
22. Beta-amyloid mediated nitration of manganese superoxide dismutase: implication for oxidative stress in a APPNLH/NLH × PS-1P264L/P264L double knock-in mouse model of Alzheimer's disease. Anantharaman M, Tangpong J, Keller JN, Murphy MP, Markesbery WR, Kiningham KK, St Clair DK, Am J Pathol 2006 168 1608 1618 10.2353/ajpath.2006.051223 16651627
23. Dynamic changes in the recovery after traumatic brain injury in mice: effect of injury severity on T2-weighted MRI abnormalities, and motor and cognitive functions. Tsenter J, Beni-Adani L, Assaf Y, Alexandrovich AG, Trembovler V, Shohami E, J Neurotrauma 2008 25 324 333 10.1089/neu.2007.0452 18373482
24. Effects of group housing on stress induced emotional and neuroendocrine alterations. Liu X, Wu R, Tai F, Ma L, Wei B, Yang X, Zhang X, Jia R, Brain Res 2013 1502 71 80 23380532
25. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Prut L, Belzung C, Eur J Pharmacol 2003 463 3 33 10.1016/S0014-2999(03)01272-X 12600700
26. The effects of JWB1-84-1 on memory-related task performance by amyloid Aβ transgenic mice and by young and aged monkeys. Sood A, Warren Beach J, Webster SJ, Terry AV, Buccafusco JJ, Neuropharmacology 2007 53 588 600 10.1016/j.neuropharm.2007.06.028 17698153
27. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Arendash GW, King DL, Gordon MN, Morgan D, Hatcher JM, Hope CE, Diamond DM, Brain Res 2001 891 42 53 10.1016/S0006-8993(00)03186-3 11164808
28. Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Alamed J, Wilcock DM, Diamond DM, Gordon MN, Morgan D, Nat Protoc 2006 1 1671 1679 10.1038/nprot.2006.275 17487150
29. Performance of different mouse strains in an object recognition task. Sik A, van Nieuwehuyzen P, Prickaerts J, Blokland A, Behav Brain Res 2003 147 49 54 10.1016/S0166-4328(03)00117-7 14659569
30. Assessments of cognitive deficits in mutant mice. Rodriguiz RM, Wetsel WC, Animal Models of Cognitive Impairment Boca Raton, FL, Levin ED, Buccafusco JJ, 2006
31. Behavioral phenotyping strategies for mutant mice. Crawley JN, Neuron 2008 57 809 818 10.1016/j.neuron.2008.03.001 18367082
32. Anxiety-like behavior in mice in two apparatuses during withdrawal from chronic ethanol vapor inhalation. Kliethermes CL, Cronise K, Crabbe JC, Alcohol Clin Exp Res 2004 28 1012 1019 10.1097/01.ALC.0000131976.40428.8F 15252287
33. Transgenic mouse models of Alzheimer's disease: behavioral testing and considerations. Bryan KJ, Lee H, Perry G, Smith MA, Casadesus G, Methods of Behavior Analysis in Neuroscience, Buccafusco JJ. Boca Raton, FL, 2 2009
34. Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease. Kobayashi DT, Chen KS, Genes Brain Behav 2005 4 173 196 10.1111/j.1601-183X.2005.00124.x 15810905
35. Regionally specific loss of neurons in the aging human hippocampus. West MJ, Neurobiol Aging 1993 14 287 293 10.1016/0197-4580(93)90113-P 8367010
36. Subcutaneous Nogo receptor removes brain amyloid-beta and improves spatial memory in Alzheimer's transgenic mice. Park JH, Widi GA, Gimbel DA, Harel NY, Lee DH, Strittmatter SM, J Neurosci 2006 26 13279 13286 10.1523/JNEUROSCI.4504-06.2006 17182778
37. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, Arancio O, Ann Neurol 2004 55 801 814 10.1002/ana.20101 15174014
38. Chronic ramelteon treatment in a mouse model of Alzheimer's disease. McKenna JT, Christie MA, Jeffrey BA, McCoy JG, Lee E, Connolly NP, Ward CP, Strecker RE, Arch Ital Biol 2012 150 5 14 22786833
39. Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine. Nagakura A, Shitaka Y, Yarimizu J, Matsuoka N, Eur J Pharmacol 2013 703 53 61 10.1016/j.ejphar.2012. 12.023 23276665
40. The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, Carlson GA, Younkin SG, Ashe KH, J Neurosci 2002 22 1858 1867 11880515
41. Mouse models of Alzheimer's disease. Hall AM, Roberson ED, Brain Res Bull 2012 88 3 12 10.1016/j.brainresbull.2011.11.017 22142973
42. Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Kimura R, Ohno M, Neurobiol Dis 2009 33 229 235 10.1016/j.nbd.2008.10.006 19026746
43. BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. Ohno M, Cole SL, Yasvoina M, Zhao J, Citron M, Berry R, Disterhoft JF, Vassar R, Neurobiol Dis 2007 26 134 145 10.1016/j.nbd.2006.12. 008 17258906
44. Oxidative damage in brain from human mutant APP/PS-1 double knock-in mice as a function of age. Abdul HM, Sultana R, St Clair DK, Markesbery WR, Butterfield DA, Free Radic Biol Med 2008 45 1420 1425 10.1016/j.freeradbiomed. 2008.08.012 18762245
45. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VM, J Neurosci 2001 21 4183 4187 11404403
46. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PL, Siedlak SL, Tabaton M, Perry G, J Neurochem 1998 70 2212 2215 9572310
47. Age-related loss of phospholipid asymmetry in APP(NLh)/APP(NLh) × PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice: relevance to Alzheimer disease. Bader Lange ML, St Clair D, Markesbery WR, Studzinski CM, Murphy MP, Butterfield DA, Neurobiol Dis 2010 38 104 115 10.1016/j.nbd.2010.01. 004 20083199
48. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD, Proc Natl Acad Sci USA 2009 106 14670 14675 10.1073/pnas.0903563106 19667196
49. Vascular cognitive impairment and Alzheimer's disease: role of cerebral hypoperfusion and oxidative stress. Kim HA, Miller AA, Drummond GR, Thrift AG, Arumugam TV, Phan TG, Srikanth VK, Sobey CG, Naunyn Schmiedebergs Arch Pharmacol 2012 385 953 959 10.1007/s00210-012-0790-7 22872171
50. Antioxidant therapies for Alzheimer's disease. Feng Y, Wang X, Oxid Med Cell Longev 2012 2012 472932 22888398
51. Motor signs during the course of Alzheimer disease. Scarmeas N, Hadjigeorgiou GM, Papadimitriou A, Dubois B, Sarazin M, Brandt J, Albert M, Marder K, Bell K, Honig LS, Wegesin D, Stern Y, Neurology 2004 63 975 982 10.1212/01.WNL.0000138440.39918.0C 15452286
52. Behavioral disturbances in transgenic mice overexpressing the V717F beta-amyloid precursor protein. Dodart JC, Meziane H, Mathis C, Bales KR, Paul SM, Ungerer A, Behav Neurosci 1999 113 982 990 10571480
53. Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation. Nilsson LN, Arendash GW, Leighty RE, Costa DA, Low MA, Garcia MF, Cracciolo JR, Rojiani A, Wu X, Bales KR, Paul SM, Potter H, Neurobiol Aging 2004 25 1153 1167 10.1016/j.neurobiolaging.2003.12.011 15312961
54. Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. Hartman RE, Izumi Y, Bales KR, Paul SM, Wozniak DF, Holtzman DM, J Neurosci 2005 25 6213 6220 10.1523/JNEUROSCI.0664-05.2005 15987951
55. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ, Justice A, McConlogue L, Games D, Freedman SB, Morris RG, Nature 2000 408 975 979 10.1038/35050103 11140684
56. Faster forgetting contributes to impaired spatial memory in the PDAPP mouse: deficit in memory retrieval associated with increased sensitivity to interference? Daumas S, Sandin J, Chen KS, Kobayashi D, Tulloch J, Martin SJ, Games D, Morris RG, Learn Mem 2008 15 625 632 10.1101/lm.990208 18772249
57. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM, Nat Neurosci 2002 5 452 457 11941374
58. Accelerated plaque accumulation, associative learning deficits, and up-regulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. Dineley KT, Xia X, Bui D, Sweatt JD, Zheng H, J Biol Chem 2002 277 22768 22780 10.1074/jbc.M200164200 11912199
59. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, Younkin L, Good MA, Bliss TV, Hyman BT, Younkin SG, Hsiao KK, Nat Neurosci 1999 2 271 276 10.1038/6374 10195221
60. Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain. Arendash GW, Lewis J, Leighty RE, McGowan E, Cracchiolo JR, Hutton M, Garcia MF, Brain Res 2004 1012 29 41 10.1016/j.brainres.2004.02.081 15158158
61. Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months. King DL, Arendash GW, Physiol Behav 2002 75 627 642 10.1016/S0031-9384(02)00639-X 12020728
62. Behavioral assessment of Alzheimer's transgenic mice following long-term Aβ vaccination: task specificity and correlations between Aβ deposition and spatial memory. Arendash GW, Gordon MN, Diamond DM, Austin LA, Hatcher JM, Jantzen P, DiCarlo G, Wilcock D, Morgan D, DNA Cell Biol 2001 20 737 744 10.1089/10445490152717604 11788052
63. Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. King DL, Arendash GW, Crawford F, Sterk T, Menendez J, Mullan MJ, Behav Brain Res 1999 103 145 162 10.1016/S0166-4328(99)00037-6 10513583
64. Transgenic mice expressing the betaAPP695SWE mutation: effects on exploratory activity, anxiety, and motor coordination. Lalonde R, Lewis TL, Strazielle C, Kim H, Fukuchi K, Brain Res 2003 977 38 45 10.1016/S0006-8993(03) 02694-5 12788511
65. Effects of the genetic background on cognitive performances of TG2576 mice. Lassalle JM, Halley H, Daumas S, Verret L, Frances B, Behav Brain Res 2008 191 104 110 10.1016/j.bbr.2008.03.017 18433892
66. Increase of locomotor activity underlying the behavioral disinhibition in tg2576 mice. Gil-Bea FJ, Aisa B, Schliebs R, Ramirez MJ, Behav Neurosci 2007 121 340 344 17469923
67. Aspects of spatial memory and behavioral disinhibition in Tg2576 transgenic mice as a model of Alzheimer's disease. Ognibene E, Middei S, Daniele S, Adriani W, Ghirardi O, Caprioli A, Laviola G, Behav Brain Res 2005 156 225 232 10.1016/j.bbr.2004.05.028 15582108
68. Overexpression of hAPPswe impairs rewarded alternation and contextual fear conditioning in a transgenic mouse model of Alzheimer's disease. Corcoran KA, Lu Y, Turner RS, Maren S, Learn Mem 2002 9 243 252 10.1101/lm.51002 12359834
69. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G, Science 1996 274 99 102 10.1126/science.274.5284.99 8810256
70. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, Vassar R, Disterhoft JF, Neuron 2004 41 27 33 10.1016/S0896-6273(03)00810-9 14715132
71. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW, Nature 2000 408 982 985 10.1038/35050116 11140686
72. Detecting spatial memory deficits beyond blindness in tg2576 Alzheimer mice. Yassine N, Lazaris A, Dorner-Ciossek C, Despres O, Meyer L, Maitre M, Mensah-Nyagan AG, Cassel JC, Mathis C, Neurobiol Aging 2013 34 716 730 10.1016/j.neurobiolaging.2012.06.016 22819136
73. Ryanodine receptor blockade reduces amyloid-beta load and memory impairments in Tg2576 mouse model of Alzheimer disease. Oules B, Del Prete D, Greco B, Zhang X, Lauritzen I, Sevalle J, Moreno S, Paterlini-Brechot P, Trebak M, Checler F, Benfenati F, Chami M, J Neurosci 2012 32 11820 11834 10.1523/JNEUROSCI.0875-12.2012 22915123
74. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Van Dam D, D'Hooge R, Staufenbiel M, Van Ginneken C, Van Meir F, De Deyn PP, Eur J Neurosci 2003 17 388 396 10.1046/j.1460-9568.2003.02444.x 12542676
75. Progressive age-related impairment of cognitive behavior in APP23 transgenic mice. Kelly PH, Bondolfi L, Hunziker D, Schlecht HP, Carver K, Maguire E, Abramowski D, Wiederhold KH, Sturchler-Pierrat C, Jucker M, Bergmann R, Staufenbiel M, Sommer B, Neurobiol Aging 2003 24 365 378 10.1016/S0197- 4580(02)00098-2 12498971
76. Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. Huang SM, Mouri A, Kokubo H, Nakajima R, Suemoto T, Higuchi M, Staufenbiel M, Noda Y, Yamaguchi H, Nabeshima T, Saido TC, Iwata N, J Biol Chem 2006 281 17941 17951 10.1074/jbc.M601372200 16636059
77. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. Heneka MT, Ramanathan M, Jacobs AH, Dumitrescu-Ozimek L, Bilkei-Gorzo A, Debeir T, Sastre M, Galldiks N, Zimmer A, Hoehn M, Heiss WD, Klockgether T, Staufenbiel M, J Neurosci 2006 26 1343 1354 10.1523/JNEUROSCI.4236-05.2006 16452658
78. Aged APP23 mice show a delay in switching to the use of a strategy in the Barnes maze. Prut L, Abramowski D, Krucker T, Levy CL, Roberts AJ, Staufenbiel M, Wiessner C, Behav Brain Res 2007 179 107 110 10.1016/j.bbr.2007.01.017 17324476
79. Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with the Swedish mutation. Lalonde R, Dumont M, Staufenbiel M, Sturchler-Pierrat C, Strazielle C, Brain Res 2002 956 36 44 10.1016/S0006-8993(02)03476-5 12426044
80. Neurobehavioral characterization of APP23 transgenic mice with the SHIRPA primary screen. Lalonde R, Dumont M, Staufenbiel M, Strazielle C, Behav Brain Res 2005 157 91 98 10.1016/j.bbr.2004.06.020 15617775
81. Spatial learning and exploration of environmental stimuli in 24-month-old female APP23 transgenic mice with the Swedish mutation. Dumont M, Strazielle C, Staufenbiel M, Lalonde R, Brain Res 2004 1024 113 121 10.1016/j.brainres.2004. 07.052 15451372
82. Age-progressing cognitive impairments and neuropathology in transgenic CRND8 mice. Hyde LA, Kazdoba TM, Grilli M, Lozza G, Brusa R, Zhang Q, Wong GT, McCool MF, Zhang L, Parker EM, Higgins GA, Behav Brain Res 2005 160 344 355 10.1016/j.bbr.2004.12.017 15863231
83. Age- and sex-dependent development of adrenocortical hyperactivity in a transgenic mouse model of Alzheimer's disease. Touma C, Ambree O, Gortz N, Keyvani K, Lewejohann L, Palme R, Paulus W, Schwarze-Eicker K, Sachser N, Neurobiol Aging 2004 25 893 904 10.1016/j.neurobiolaging.2003.09.004 15212843
84. Levodopa ameliorates learning and memory deficits in a murine model of Alzheimer's disease. Ambree O, Richter H, Sachser N, Lewejohann L, Dere E, de Souza Silva MA, Herring A, Keyvani K, Paulus W, Schabitz WR, Neurobiol Aging 2009 30 1192 1204 10.1016/j.neurobiolaging.2007.11.010 18079024
85. Age-related increase in amyloid plaque burden is associated with impairment in conditioned fear memory in CRND8 mouse model of amyloidosis. Hanna A, Iremonger K, Das P, Dickson D, Golde T, Janus C, Alzheimers Res Ther 2012 4 21 10.1186/alzrt124 22697412
86. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zuker N, Loukides J, French J, Turner S, Lozza G, Grilli M, Kunicki S, Morissette C, Paquette J, Gervais F, Bergeron C, Fraser PE, Carlson GA, George-Hyslop PS, Westaway D, J Biol Chem 2001 276 21562 21570 10.1074/jbc.M100710200 11279122
87. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D, Nature 2000 408 979 982 10.1038/35050110 11140685
88. Effects of environmental enrichment on exploration, anxiety, and memory in female TgCRND8 Alzheimer mice. Gortz N, Lewejohann L, Tomm M, Ambree O, Keyvani K, Paulus W, Sachser N, Behav Brain Res 2008 191 43 48 10.1016/j.bbr.2008.03.006 18433890
89. Wheel-running in a transgenic mouse model of Alzheimer's disease: protection or symptom? Richter H, Ambree O, Lewejohann L, Herring A, Keyvani K, Paulus W, Palme R, Touma C, Schabitz WR, Sachser N, Behav Brain Res 2008 190 74 84 10.1016/j.bbr.2008.02.005 18342378
90. Cholinergic dysfunction, neuronal damage and axonal loss in TgCRND8 mice. Bellucci A, Luccarini I, Scali C, Prosperi C, Giovannini MG, Pepeu G, Casamenti F, Neurobiol Dis 2006 23 260 272 10.1016/j.nbd.2006.03.012 16766197
91. Working memory impairment in a transgenic amyloid precursor protein TgCRND8 mouse model of Alzheimer's disease. Lovasic L, Bauschke H, Janus C, Genes Brain Behav 2005 4 197 208 10.1111/j.1601-183X.2004.00104.x 15810906
92. Search strategies used by APP transgenic mice during navigation in the Morris water maze. Janus C, Learn Mem 2004 11 337 346 10.1101/lm.70104 15169864
93. Amyloid beta and impairment in multiple memory systems in older transgenic APP TgCRND8 mice. Hanna A, Horne P, Yager D, Eckman C, Eckman E, Janus C, Genes Brain Behav 2009 8 676 684 10.1111/j.1601-183X.2009.00510.x 19531156
94. Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein. Harris JA, Devidze N, Halabisky B, Lo I, Thwin MT, Yu GQ, Bredesen DE, Masliah E, Mucke L, J Neurosci 2010 30 372 381 10.1523/JNEUROSCI.5341-09.2010 20053918
95. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, Puolivali J, Lesne S, Ashe KH, Muchowski PJ, Mucke L, J Biol Chem 2007 282 23818 23828 10.1074/jbc.M701078200 17548355
96. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Sanchez-Mejia RO, Newman JW, Toh S, Yu GQ, Zhou Y, Halabisky B, Cisse M, Scearce-Levie K, Cheng IH, Gan L, Palop JJ, Bonventre JV, Mucke L, Nat Neurosci 2008 11 1311 1318 10.1038/nn.2213 18931664
97. Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. Saura CA, Chen G, Malkani S, Choi SY, Takahashi RH, Zhang D, Gouras GK, Kirkwood A, Morris RG, Shen J, J Neurosci 2005 25 6755 6764 10.1523/JNEUROSCI.1247-05.2005 16033885
98. ABAD directly links Aβ to mitochondrial toxicity in Alzheimer's disease. Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, Caspersen C, Chen X, Pollak S, Chaney M, Trinchese F, Liu S, Gunn-Moore F, Lue LF, Walker DG, Kuppusamy P, Zewier ZL, Arancio O, Stern D, Yan SS, Wu H, Science 2004 304 448 452 10.1126/science.1091230 15087549
99. Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease. Meilandt WJ, Yu GQ, Chin J, Roberson ED, Palop JJ, Wu T, Scearce-Levie K, Mucke L, J Neurosci 2008 28 5007 5017 10.1523/JNEUROSCI.0590-08.2008 18463254
100. Overexpression of wild-type human APP in mice causes cognitive deficits and pathological features unrelated to Aβ levels. Simon AM, Schiapparelli L, Salazar-Colocho P, Cuadrado-Tejedor M, Escribano L, Lopez de Maturana R, Del Rio J, Perez-Mediavilla A, Frechilla D, Neurobiol Dis 2009 33 369 378 10.1016/j.nbd.2008.11.005 19101630
101. Cyclophilin D deficiency improves mitochondrial function and learning/memory in aging Alzheimer disease mouse model. Du H, Guo L, Zhang W, Rydzewska M, Yan S, Neurobiol Aging 2011 32 398 406 10.1016/j.neurobiolaging. 2009.03.003 19362755
102. Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice. Cisse M, Sanchez PE, Kim DH, Ho K, Yu GQ, Mucke L, J Neurosci 2011 31 10427 10431 10.1523/JNEUROSCI.1459-11.2011 21775587
103. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Palop JJ, Jones B, Kekonius L, Chin J, Yu GQ, Raber J, Masliah E, Mucke L, Proc Natl Acad Sci USA 2003 100 9572 9577 10.1073/pnas.1133381100 12881482
104. Multi-faced neuroprotective effects of Ginsenoside Rg1 in an Alzheimer mouse model. Fang F, Chen X, Huang T, Lue LF, Luddy JS, Yan SS, Biochim Biophys Acta 2012 1822 286 292 10.1016/j.bbadis.2011.10.004 22015470
105. Insulin receptor mutation results in insulin resistance and hyperinsulinemia but does not exacerbate Alzheimer's-like phenotypes in mice. Murakami K, Yokoyama S, Murata N, Ozawa Y, Irie K, Shirasawa T, Shimizu T, Biochem Biophys Res Commun 2011 409 34 39 10.1016/j.bbrc.2011.04.101 21549686
106. Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Escribano L, Simon AM, Perez-Mediavilla A, Salazar-Colocho P, Del Rio J, Frechilla D, Biochem Biophys Res Commun 2009 379 406 410 10.1016/j.bbrc.2008.12.071 19109927
107. Cognitive phenotyping of amyloid precursor protein transgenic J20 mice. Karl T, Bhatia S, Cheng D, Kim WS, Garner B, Behav Brain Res 2012 228 392 397 10.1016/j.bbr.2011.12.021 22197298
108. Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Galvan V, Gorostiza OF, Banwait S, Ataie M, Logvinova AV, Sitaraman S, Carlson E, Sagi SA, Chevallier N, Jin K, Greenberg DA, Bredesen DE, Proc Natl Acad Sci USA 2006 103 7130 7135 10.1073/pnas. 0509695103 16641106
109. Early-onset subicular microvascular amyloid and neuroinflammation correlate with behavioral deficits in vasculotropic mutant amyloid beta-protein precursor transgenic mice. Xu F, Grande AM, Robinson JK, Previti ML, Vasek M, Davis J, Van Nostrand WE, Neuroscience 2007 146 98 107 10.1016/j.neuroscience. 2007.01.043 17331655
110. Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid. Fan R, Xu F, Previti ML, Davis J, Grande AM, Robinson JK, Van Nostrand WE, J Neurosci 2007 27 3057 3063 10.1523/JNEUROSCI.4371-06.2007 17376966
111. Exploratory activity, anxiety, and motor coordination in bigenic APPswe + PS1/DeltaE9 mice. Lalonde R, Kim HD, Fukuchi K, Neurosci Lett 2004 369 156 161 10.1016/j.neulet.2004.07.069 15450687
112. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. Cao D, Lu H, Lewis TL, Li L, J Biol Chem 2007 282 36275 36282 10.1074/jbc.M703561200 17942401
113. Impaired spatial learning in the APPSwe + PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease. Reiserer RS, Harrison FE, Syverud DC, McDonald MP, Genes Brain Behav 2007 6 54 65 10.1111/j.1601-183X.2006.00221.x 17233641
114. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE, Science 2012 335 1503 1506 10.1126/science.1217697 22323736
115. Episodic memory deficits are not related to altered glutamatergic synaptic transmission and plasticity in the CA1 hippocampus of the APPswe/PS1deltaE9-deleted transgenic mice model of ss-amyloidosis. Volianskis A, Kostner R, Molgaard M, Hass S, Jensen MS, Neurobiol Aging 2010 31 1173 1187 10.1016/j.neurobiolaging.2008.08.005 18790549
116. Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model. Ding Y, Qiao A, Wang Z, Goodwin JS, Lee ES, Block ML, Allsbrook M, McDonald MP, Fan GH, J Neurosci 2008 28 11622 11634 10.1523/JNEUROSCI.3153-08.2008 18987198
117. Elimination of GD3 synthase improves memory and reduces amyloid-beta plaque load in transgenic mice. Bernardo A, Harrison FE, McCord M, Zhao J, Bruchey A, Davies SS, Jackson Roberts L, Mathews PM, Matsuoka Y, Ariga T, Yu RK, Thompson R, McDonald MP, Neurobiol Aging 2009 30 1777 1791 10.1016/j. neurobiolaging.2007.12.022 18258340
118. Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice. Ma T, Du X, Pick JE, Sui G, Brownlee M, Klann E, J Neurosci 2012 32 13701 13708 10.1523/JNEUROSCI.2107-12.2012 23035082
119. Exploratory activity and spatial learning in 12-month-old APP(695)SWE/co+PS1/DeltaE9 mice with amyloid plaques. Lalonde R, Kim HD, Maxwell JA, Fukuchi K, Neurosci Lett 2005 390 87 92 10.1016/j.neulet.2005.08.028 16169151
120. Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease. Zhang W, Hao J, Liu R, Zhang Z, Lei G, Su C, Miao J, Li Z, Behav Brain Res 2011 222 342 350 10.1016/j.bbr.2011.03.072 21513747
121. Morphological alterations to neurons of the amygdala and impaired fear conditioning in a transgenic mouse model of Alzheimer's disease. Knafo S, Venero C, Merino-Serrais P, Fernaud-Espinosa I, Gonzalez-Soriano J, Ferrer I, Santpere G, DeFelipe J, J Pathol 2009 219 41 51 10.1002/path.2565 19449368
122. Visuo-spatial learning and memory deficits on the Barnes maze in the 16-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease. O'Leary TP, Brown RE, Behav Brain Res 2009 201 120 127 10.1016/j.bbr.2009.01.039 19428625
123. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K, Nat Med 1998 4 97 100 10.1038/nm0198-097 9427614
124. Amyloid-beta deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP/PS1 mice. Sadowski M, Pankiewicz J, Scholtzova H, Ji Y, Quartermain D, Jensen CH, Duff K, Nixon RA, Gruen RJ, Wisniewski T, J Neuropathol Exp Neurol 2004 63 418 428 15198121
125. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan D, Behav Genet 1999 29 177 185 10.1023/A:1021691918517 10547924
126. Ferulic acid is a nutraceutical beta-secretase modulator that improves behavioral impairment and Alzheimer-like pathology in transgenic mice. Mori T, Koyama N, Guillot-Sestier MV, Tan J, Town T, PLoS One 2013 8 55774 10.1371/journal.pone.0055774 23409038
127. Correlation between cognitive deficits and Aβ deposits in transgenic APP+PS1 mice. Gordon MN, King DL, Diamond DM, Jantzen PT, Boyett KV, Hope CE, Hatcher JM, DiCarlo G, Gottschall WP, Morgan D, Arendash GW, Neurobiol Aging 2001 22 377 385 10.1016/S0197-4580(00)00249-9 11378242
128. Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D, J Neuroinflammation 2004 1 24 10.1186/1742-2094-1-24 15588287
129. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R, J Neurosci 2006 26 10129 10140 10.1523/JNEUROSCI.1202-06.2006 17021169
130. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease. Jawhar S, Trawicka A, Jenneckens C, Bayer TA, Wirths O, Neurobiol Aging 2012 33 196.e129 e140
131. A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice. Shukla V, Zheng YL, Mishra SK, Amin ND, Steiner J, Grant P, Kesavapany S, Pant HC, FASEB J 2013 27 174 186 10.1096/fj.12-217497 23038754
132. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein WL, Vassar R, Disterhoft JF, Eur J Neurosci 2006 23 251 260 10.1111/j.1460-9568. 2005.04551.x 16420434
133. Identification of low molecular weight pyroglutamate A[44] oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. Wirths O, Erck C, Martens H, Harmeier A, Geumann C, Jawhar S, Kumar S, Multhaup G, Walter J, Ingelsson M, Degerman-Gunnarsson M, Kalimo H, Huitinga I, Lannfelt L, Bayer TA, J Biol Chem 2010 285 41517 41524 10.1074/jbc.M110.178707 20971852
134. Genetic reductions of beta-site amyloid precursor protein-cleaving enzyme 1 and amyloid-beta ameliorate impairment of conditioned taste aversion memory in 5XFAD Alzheimer's disease model mice. Devi L, Ohno M, Eur J Neurosci 2010 31 110 118 10.1111/j.1460-9568.2009.07031.x 20092558
135. Mitochondrial dysfunction and accumulation of the beta-secretase-cleaved C-terminal fragment of APP in Alzheimer's disease transgenic mice. Devi L, Ohno M, Neurobiol Dis 2012 45 417 424 10.1016/j.nbd.2011.09.001 21933711
136. Diosgenin is an exogenous activator of 1,25D(3)-MARRS/Pdia3/ERp57 and improves Alzheimer's disease pathologies in 5XFAD mice. Tohda C, Urano T, Umezaki M, Nemere I, Kuboyama T, Sci Rep 2012 2 535 22837815
137. Icariin improves memory impairment in Alzheimer's disease model mice (5xFAD) and attenuates amyloid beta-induced neurite atrophy. Urano T, Tohda C, Phytother Res 2010 24 1658 1663 10.1002/ptr.3183 21031624
138. Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM, Neuron 2005 45 675 688 10.1016/j.neuron.2005. 01.040 15748844
139. Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. Clinton LK, Billings LM, Green KN, Caccamo A, Ngo J, Oddo S, McGaugh JL, LaFerla FM, Neurobiol Dis 2007 28 76 82 10.1016/j.nbd.2007.06.013 17659878
140. Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid. Gimenez-Llort L, Blazquez G, Canete T, Johansson B, Oddo S, Tobena A, LaFerla FM, Fernandez-Teruel A, Neurosci Biobehav Rev 2007 31 125 147 10.1016/j.neubiorev.2006.07.007 17055579
141. Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. Carroll JC, Rosario ER, Chang L, Stanczyk FZ, Oddo S, LaFerla FM, Pike CJ, J Neurosci 2007 27 13357 13365 10.1523/JNEUROSCI.2718-07. 2007 18045930
142. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Nelson RL, Guo Z, Halagappa VM, Pearson M, Gray AJ, Matsuoka Y, Brown M, Martin B, Iyun T, Maudsley S, Clark RF, Mattson MP, Exp Neurol 2007 205 166 176 10.1016/j.expneurol.2007.01.037 17368447
143. Age-dependent phenotypic characteristics of a triple transgenic mouse model of Alzheimer disease. Pietropaolo S, Feldon J, Yee BK, Behav Neurosci 2008 122 733 747 18729626
144. Limited impact of social isolation on Alzheimer-like symptoms in a triple transgenic mouse model. Pietropaolo S, Sun Y, Li R, Brana C, Feldon J, Yee BK, Behav Neurosci 2009 123 181 195 19170443
145. Characterization of the 3xTg-AD mouse model of Alzheimer's disease: part 2. Behavioral and cognitive changes. Sterniczuk R, Antle MC, Laferla FM, Dyck RH, Brain Res 2010 1348 149 155 20558146
146. DHA improves cognition and prevents dysfunction of entorhinal cortex neurons in 3xTg-AD mice. Arsenault D, Julien C, Tremblay C, Calon F, PLoS One 2011 6 17397 10.1371/journal.pone.0017397 21383850
147. Cognitive and non-cognitive behaviors in the triple transgenic mouse model of Alzheimer's disease expressing mutated APP, PS1, and Mapt (3xTg-AD). Filali M, Lalonde R, Theriault P, Julien C, Calon F, Planel E, Behav Brain Res 2012 234 334 342 10.1016/j.bbr.2012.07.004 22796601
148. Which memory task for my mouse? A systematic review of spatial memory performance in the Tg2576 Alzheimer's mouse model. Stewart S, Cacucci F, Lever C, J Alzheimers Dis 2011 26 105 126 21971455
149. Validation of a 2-day water maze protocol in mice. Gulinello M, Gertner M, Mendoza G, Schoenfeld BP, Oddo S, LaFerla F, Choi CH, McBride SM, Faber DS, Behav Brain Res 2009 196 220 227 10.1016/j.bbr.2008.09.002 18831990
150. Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease. Halagappa VK, Guo Z, Pearson M, Matsuoka Y, Cutler RG, Laferla FM, Mattson MP, Neurobiol Dis 2007 26 212 220 10.1016/j.nbd.2006.12.019 17306982
151. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, Montoya-Zavala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, et al. Nature 1995 373 523 527 10.1038/373523a0 7845465
152. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B, Proc Natl Acad Sci USA 1997 94 13287 13292 10.1073/pnas.94.24.13287 9371838
153. High-level neuronal expression of aβ 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L, J Neurosci 2000 20 4050 4058 10818140
154. Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. Davis J, Xu F, Deane R, Romanov G, Previti ML, Zeigler K, Zlokovic BV, Van Nostrand WE, J Biol Chem 2004 279 20296 20306 10.1074/jbc.M312946200 14985348
155. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR, Biomol Eng 2001 17 157 165 10.1016/S1389-0344(01)00067-3 11337275
156. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM, Neuron 2003 39 409 421 10.1016/S0896-6273(03)00434-3 12895417